Đang chuẩn bị liên kết để tải về tài liệu:
A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients

Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ

The aim of this study was to determine whether checkpoint kinase 1 inihibitor (CHK1), LY2603618, and gemcitabine prolong overall survival (OS) compared to gemcitabine alone in patients with unresectable pancreatic cancer. |

TÀI LIỆU LIÊN QUAN

NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma

Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: Study protocol for a multicenter randomized phase II trial (the OCUU-CRPC study)

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer

Efficacy and safety of weekly nab-paclitaxel plus gemcitabine in Chinese patients with metastatic adenocarcinoma of the pancreas: A phase II study

Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study

Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer

Examestane in advanced or recurrent endometrial carcinoma: A prospective phase II study by the Nordic Society of Gynecologic Oncology (NSGO)

Long-term results of radiotherapy combined with nedaplatin and 5-fluorouracil for postoperative loco-regional recurrent esophageal cancer: Update on a phase II study

The WIRE study a phase II, multi-arm, multicentre, non-randomised window-ofopportunity clinical trial platform using a Bayesian adaptive design for proof-ofmechanism of novel treatment strategies in operable renal cell cancer – a study protocol